160 related articles for article (PubMed ID: 2826175)
1. The selective kappa-opioid agonist, U-50,488H, produces antinociception in the rat via a supraspinal action.
Czlonkowski A; Millan MJ; Herz A
Eur J Pharmacol; 1987 Oct; 142(1):183-4. PubMed ID: 2826175
[No Abstract] [Full Text] [Related]
2. Role of spinal kappa opioid receptors in the blockade of the development of antinociceptive tolerance to morphine.
Takahashi M; Senda T; Kaneto H
Eur J Pharmacol; 1991 Aug; 200(2-3):293-7. PubMed ID: 1664330
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of the antinociceptive action of the selective kappa-opioid receptor agonist, U-50,488H by ICS-205-930.
Ho BY; Takemori AE
Eur J Pharmacol; 1990 Mar; 178(3):371-3. PubMed ID: 2160372
[TBL] [Abstract][Full Text] [Related]
4. Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats.
Fukagawa Y; Katz JL; Suzuki T
Eur J Pharmacol; 1989 Oct; 170(1-2):47-51. PubMed ID: 2558895
[TBL] [Abstract][Full Text] [Related]
5. A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats.
Yamamoto T; Ohno M; Ueki S
Eur J Pharmacol; 1988 Oct; 156(1):173-6. PubMed ID: 2850208
[TBL] [Abstract][Full Text] [Related]
6. Contribution of supraspinal mu- and delta-opioid receptors to antinociception in the rat.
Miaskowski C; Taiwo YO; Levine JD
Eur J Pharmacol; 1991 Dec; 205(3):247-52. PubMed ID: 1667910
[TBL] [Abstract][Full Text] [Related]
7. Selective kappa opioid agonist for spinal analgesia without the risk of respiratory depression.
Castillo R; Kissin I; Bradley EL
Anesth Analg; 1986 Apr; 65(4):350-4. PubMed ID: 3006552
[TBL] [Abstract][Full Text] [Related]
8. Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by mu-opioid agonists, but not by delta- and kappa-opioid agonists.
Kamei J; Ohhashi Y; Aoki T; Kawasima N; Kasuya Y
Brain Res; 1992 Feb; 571(2):199-203. PubMed ID: 1319265
[TBL] [Abstract][Full Text] [Related]
9. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse.
Porreca F; Mosberg HI; Hurst R; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1984 Aug; 230(2):341-8. PubMed ID: 6086883
[TBL] [Abstract][Full Text] [Related]
10. Role of vagal afferents in the antinociception produced by morphine and U-50,488H in the colonic pain reflex in rats.
Diop L; Rivière PJ; Pascaud X; Dassaud M; Junien JL
Eur J Pharmacol; 1994 May; 257(1-2):181-7. PubMed ID: 8082700
[TBL] [Abstract][Full Text] [Related]
11. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
Millan MJ; Członkowski A; Lipkowski A; Herz A
J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
[TBL] [Abstract][Full Text] [Related]
12. Tonic pain perception in the mouse: differential modulation by three receptor-selective opioid agonists.
Murray CW; Cowan A
J Pharmacol Exp Ther; 1991 Apr; 257(1):335-41. PubMed ID: 1850470
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of a selective kappa receptor agonist, U-50, 488H, on methamphetamine-elicited ipsilateral circling behavior in rats with unilateral nigral lesions.
Ohno M; Yamamoto T; Ueki S
Psychopharmacology (Berl); 1989; 97(2):219-21. PubMed ID: 2543013
[TBL] [Abstract][Full Text] [Related]
14. Effects of morphine in rats treated chronically with U-50,488 H, a kappa opioid receptor agonist.
Bhargava HN; Ramarao P; Gulati A
Eur J Pharmacol; 1989 Mar; 162(2):257-64. PubMed ID: 2542058
[TBL] [Abstract][Full Text] [Related]
15. Haloperidol pretreatment unmasks the kappa opioid effects of U-50, 488H on cortical EEG and EEG power spectra in rats.
Young GA; Marquis KL; Paquette NC; Gussio RP; Khazan N
Neuropharmacology; 1989 Aug; 28(8):881-4. PubMed ID: 2550842
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.
Pugsley MK; Penz WP; Walker MJ; Wong TM
Br J Pharmacol; 1992 Mar; 105(3):521-6. PubMed ID: 1320979
[TBL] [Abstract][Full Text] [Related]
17. Effect of chronic administration of U-50,488H on tolerance to its pharmacological actions and on multiple opioid receptors in rat brain regions and spinal cord.
Bhargava HN; Gulati A; Ramarao P
J Pharmacol Exp Ther; 1989 Oct; 251(1):21-6. PubMed ID: 2552075
[TBL] [Abstract][Full Text] [Related]
18. Antinociception produced by receptor selective opioids: modulation of spinal antinociceptive effects by supraspinal opioids.
Miaskowski C; Levine JD
Brain Res; 1992 Nov; 595(1):32-8. PubMed ID: 1334770
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of central receptors for thyrotropin-releasing hormone in kappa opiate agonist-induced abstinence in the rat.
Bhargava HN; Gulati A; Rahmani NH
Neuropharmacology; 1992 Feb; 31(2):137-41. PubMed ID: 1313157
[TBL] [Abstract][Full Text] [Related]
20. A kappa opiate agonist, U50,488H, enhances energy expenditure in rats.
Mandenoff A; Seyrig JA; Betoulle D; Brigant L; Melchior JC; Apfelbaum M
Pharmacol Biochem Behav; 1991 May; 39(1):215-7. PubMed ID: 1656474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
